The Conversation (0)
Vernalis Plc (LSE:VER) completed the CCP-01
Pivotal Single Dose comparative bioavailability study successfully. CCP-01 is the first product being developed for Vernalis by Tris Pharma for the US prescription cough cold market.
Vernalis Plc (LSE:VER) completed the CCP-01 Pivotal Single Dose comparative bioavailability study successfully. CCP-01 is the first product being developed for Vernalis by Tris Pharma for the US prescription cough cold market.
As quoted in the press release:
Vernalis plc today announces successful completion of the CCP-01 Pivotal Single Dose comparative bioavailability study.
CCP-01 is the first product being developed for Vernalis by Tris Pharma
for the US prescription cough cold market. It will now move into a multi-dose comparative bioavailability study and continues in 12 month stability studies. Subject to the successful outcome of these studies, filing of the NDA for CCP-01 with the FDA remains on track to be made in mid-2014.
Vernalis Plc CEO, Ian Garland, said:
We are delighted with these results and the continued progression of this project and our collaboration with Tris.
Click here to read the Vernalis Plc (LSE:VER) press release
